Merck (MSD) has reported that its Keytruda met the primary goal of overall survival (OS) in Phase III KEYNOTE-355 trial involving patients with metastatic triple-negative breast cancer (mTNBC).
Serono Inc`s Biological Interferon Beta-1A Receives Supplemental Approval In US
The continuing development of digital communication in pharma and healthcare was highlighted last night at the PM Society Digital Awards in London.
ROCKLAND, Mass., Aug. 31, 2018 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced that Rehan Verjee has been appointed President of EMD Serono and Global Head of Innovative Medicine Franchises, Merck KGaA, Darmstadt, Germany.
Annalisa Jenkins has worked at quite a few places. Before she was the leader of the gene therapy player Dimension — bought out by Ultragenyx $RARE after a setback on the lead program — she has held global R&D positions at Bristol-Myers Squibb $BMY and Merck Serono after leaving the British Royal Navy. And each offered something that the other couldn’t exactly replace.
He will work with Mackay (who retires at the end of the year) to take over as EVP and head of research & development and joins from a very short stint at rare disease biotech Novelion, where he had been head of research since November last year. Before then, was global head of R&D and CSO at Baxalta, with former roles at Baxter International (also the former home of Alexion's new CEO), Merck Serono, Novartis and Merck Research Laboratories.
Last year, ex-Pfizer exec Geno Germano joined synthetic biology firm Intrexon as president and CEO-in-waiting, intent on helping the company push forward its portfolio of human medicines. Fast-forward a few months, and Germano is leaving, prompted by a restructuring that has stripped those health-related programs from under him.nnThe biotech—headed by billionaire Randal J. Kirk—has decided to spin out all of its human health projects into a separate company called Precigen, and will instead focus on biological engineering programs in other sectors such as food, energy and environmental science. All worthy projects—but outside Germano's core expertise.
Sanofi has contracted Swiss biotech Selexis SA to develop cell lines for a three early stage projects.
Merck KGaA's US biopharmaceutical business EMD Serono has appointed Richard Smith as senior vice president and head of US fertility and endocrinology.
On 29 November 2016 (before trading hours), Tongfang Kontafarma entered into a share subscription agreement with Binex and its majority shareholders, pursuant to which the Group has conditionally agreed to subscribe, and the Target Company has conditionally agreed to issue to the Group, the subscription shares, representing (i) approximately 29% of the total issued share capital of the Target Company as enlarged by the subscription shares immediately upon completion of the subscription; and (ii) approximately 28% of the total issued share capital of the Target Company as enlarged by the subscription shares and assuming that all the outstanding convertible bonds and employees share options of the Target Company are fully converted and exercised.